Tirrell Tremayne Johnson, MD
Dr. Tirrell Tremayne Johnson is a medical oncologist and member of the Hematology and Thoracic/Head and Neck Cancers Specialty sections at Orlando Health Cancer Institute in Orlando, Florida. He specializes in treating patients diagnosed with thoracic cancers, including lung cancer, malignant pleural mesothelioma, and thymoma, as well as cancers affecting the head and neck.[1]
Dr. Johnson works with a multidisciplinary team at Orlando Health Cancer Institute to create optimal treatment plans based on their individual disease state and goals. He prioritizes ensuring that his patients understand their disease process and the options available to them, thoroughly explaining the protocols available so they can make good decisions.
Education and Career
After graduating magna cum laude from Florida A&M University with a bachelor’s degree in chemical engineering, Dr. Johnson earned his medical degree from the University of Florida, where he was awarded the Mark Herrbold Award recognizing his outstanding academic accomplishments during the first three years of medical school. He completed an internship and residency in Internal Medicine at Orlando Regional Medical Center and a fellowship in Hematology and Oncology from Roger Williams Medical Center at the Brown University Medical School.[1]
Dr. Johnson is board-certified in Internal Medicine and Medical Oncology and is a member of the American College of Physicians, the American Society of Clinical Oncology, and the American Society of Hematology.
Research
Dr. Johnson is actively involved in medical research and has served as the primary investigator for clinical trials investigating several forms of chemotherapy for advanced head and neck cancers and thoracic malignancies.[1]
His recent work includes:[2]
Clinical Trials
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaStart of enrollment: 2010 Mar 15. ACTIVE. PHASE 1, PHASE 2.
Publications & Presentations
- Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Char…>; Clinical Cancer Research. 2017 Oct 1
- Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. Neal Ready, Ritesh Rathore, Tirrell T. Johnson, A. Nadeem, Prakash Chougule, Charles Ruhl, K. Radie-Keane, Kathy Puyana Theall, Harold J. Wanebo, Jennifer Marcello, Te…>; American Journal of Clinical Oncology. 2012 Feb 1
